source xi o target CD20 Clinical data tradename Rituxan Drugs.com drugs.com monograph rituximab pregnancy ... molecular weight 143859.7 g mol Rituximab trade names Rituxan and MabThera , is a Chimera protein ... cells . Rituximab destroys B cells, and is therefore used to treat diseases which are characterized ... s, leukemia s, transplant rejection and some autoimmune disorder s. History Rituximab was developed ..., et al. title IDEC C2B8 Rituximab anti CD20 monoclonal antibody therapy in patients with relapsed ... pmid 9310469 doi url http www.bloodjournal.org cgi pmidlookup?view long&pmid 9310469 ref rituximab ... s resistant to other chemotherapy regimens. ref cite journal author Scott SD title Rituximab a new ... Rituximab, in combination with CHOP chemotherapy, is superior to CHOP alone in the treatment of diffuse ... 29, 2010 ref Rituximab is currently co marketed by Biogen Idec and Genentech in the U.S., by Hoffmann .... Uses Rituximab destroys both normal and malignant B cells that have CD20 on their surfaces, and is therefore ... B cells or dysfunctional B cells. Hematological neoplastic diseases Rituximab is used to treat Hematological malignancy hematological neoplasms such as leukemia s and lymphoma s.The use of rituximab ..., Peccatori FA title Rituximab in Hodgkin lymphoma Is the target always a hit? journal Cancer Treat Rev ... myeloma , treatment with rituximab fails to deplete circulating CD20 B or plasma cells, even after up to four cycles of treatment in some patients, rituximab treatment increases the number of circulating ... includes CD20 B and plasma cells that persist in patients treated with rituximab. LM Pilarski ..., 2008 ref Autoimmune diseases Rituximab has been shown to be an effective rheumatoid arthritis treatment ... P, Close D, Stevens R, Shaw T title Efficacy of B cell targeted therapy with rituximab in patients ... safety , in a range of other autoimmune diseases, and rituximab is widely used off ... 7 676 NEJM B Cell Depletion with Rituximab in Relapsing Remitting Multiple Sclerosis ref systemic ... more details
Chemoimmunotherapy is chemotherapy combined with immunotherapy . Chemotherapy uses different drugs to kill or slow the growth of cancer cells immunotherapy uses treatments to stimulate or restore the ability of the immune system to fight cancer. A common chemoimmunotherapy regimen is CHOP combined with rituximab CHOP R for B cell non Hodgkin lymphoma s. External links http www.cancer.gov Templates db alpha.aspx?CdrID 270867 NCI Dictionary of Cancer Terms Definition of chemoimmunotherapy Category Antineoplastic drugs oncology stub ... more details
Orphan date February 2009 ICE is a combination chemotherapy regimen employing three drugs ifosfamide i fosfamide trade name Ifex , carboplatin c arboplatin trade name Paraplatin , and etoposide e toposide trade names VP 16, VePesid . This regimen is commonly used to treat primary progressive and poor risk recurrent lymphoma s. ref Follow up Care & Relapse. Lymphoma Research Foundation. http www.lymphoma.org site pp.aspx?c chKOI6PEImE&b 1574015&printmode 1 ref In the last few years, it has become more common to include the drug rituximab alongside the ICE protocol, a regimen commonly referred to as R ICE . Rituximab is a monoclonal antibody which binds to and helps destroy B cell s. ref Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan ROAD in Patients With Relapsed Non Hodgkins Lymphoma. ClinicalTrials.gov. http clinicaltrials.gov show NCT00166439 ref References reflist DEFAULTSORT Ice Chemotherapy Regimen Category Chemotherapy regimens ... more details
RTX may refer to RTX Red Rock , an action adventure game for the PlayStation 2, which was developed and published by LucasArts Royal Trux , as an abbreviation for the name of the band Resiniferatoxin , a natural, high potency ligand that activates the capsaicin font color 0 capsaicin font VR1, TRPV1 receptor The name of a firm involved in the defense industry featured in the film The Falcon and the Snowman A brand of external RAID storage by manufacturer WiebeTech. The acronym stands for RAIDTech X where X is a variable number of bays. Real Time eXtensions for Windows 7 NT 2000 XP XPe Vista made by IntervalZero RTX2010 , a radiation hardened microprocessor which has been used in numerous spacecraft RTX toxin a type of toxin secreted by Gram negative bacteria font color 0 Gram negative bacteria font RTX stands for r epeats in t o x in Rituximab , a monoclonal antibody used in the treatment of leukemia, lymphomas, transplant rejection and autoimmune disorders RTX or Rooster Teeth Expo, the official fan convention for Rooster Teeth Productions . disambiguation ... more details
Orphan date February 2009 Panel Reactive Antibody PRA is a blood test that is routinely performed on patients waiting for kidney transplant kidney and heart transplant s and measures anti human antibodies in the blood. The PRA score is given as a percentage and can be from 0 to 99 . The PRA represents the percentage of the U.S. population that the anti human antibody in your blood reacts with. Patients develop anti HLA Human Leukocyte Antigen antibodies from exposure to HLA of other humans through previous transplants, blood transfusions and or pregnancy. Patients showing high Panel Reactive Antibodies are often referred to as sensitized. Patients with high PRA usually 50 are less likely to receive transplants as the risk for immediate antibody mediated rejection of the transplanted organ is significantly increased. Treatments to reduce PRA in sensitized transplant candidates exist including treatment with Rituximab a B cell specific antibody , IVIg , protein A immunoabsorption, plasmapheresis etc. Reference Jordan and Pescovitz, Clin J Am Soc Nephrol 1 421 432, 2006 http cjasn.asnjournals.org cgi content full 1 3 421 . Category Immune system ... more details
Orphan date February 2009 Reditux is the trade name of an intended copy of rituximab , an anti CD20 antibody used in the treatment of certain lymphoma s, leukaemia s and rheumatoid arthritis . Reditux is produced by Dr reddy s Dr. Reddy s Laboratories , India s largest pharmaceutical company. Reditux was launched on April 30th, 2007 in Hydrabad, India. ref http www.biomarketgroup.com content view 122 7 Extended Views Dr Reddy s Indian generic Rituxan launch flashes warning to biologics industry ref Unlike conventional small molecule medicines, which can easily be copied and manufactured, large biological molecules such as antibodies cannot hence the term biosimilar . Biosimilars may have different molecular structure, purity, and functional characteristics, and consequently they cannot be considered the same molecule in the way that many generic medicines can . The safety and efficacy of Reditux has yet to be proven in a published clinical trial. References reflist Category Monoclonal antibodies for tumors antineoplastic drug stub Some South American countries have questioned the security of this drug. http elcomercio.pe lima 724847 noticia cuestionan cualidades farmaco usado tratamientos oncologicos 1 ... more details
Multiple issues orphan March 2012 unreferenced March 2010 Curaxys is a biopharmaceutical company specializing in the research, development and production of biosimilar generic biological drugs. The company is located in the Technological Park of Puerto de Santa Maria, in Cadiz , Spain . Curaxys has been the pioneer citation needed date December 2011 in the use of insect cells in the production of biosimilar drugs. Previously, the insect cell culture platform was used solely for vaccine production, and never for other therapeutic proteins . citation needed date March 2012 Curaxys is also developing new technological platforms based on such other expression system s as bacteria , virus es and yeast . The company is developing the recombinant proteins Insulin , Growth Hormone , Erythropoietin , and Granulocyte colony stimulating factor GCSF it is also developing the Monoclonal antibody monoclonal antibodies Rituximab and Trastuzumab . Other therapeutic proteins are under development, including non monoclonal antibodies . Category Pharmaceutical companies of Spain ... more details
non Hodgkin s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen. ref cite web url http www.cephalon.com media news releases article ... , prednisone , rituximab , vincristine and sup 90 sup Y ibritumomab tiuxetan . One combination ... prior rituximab containing chemoimmunotherapy treatment, is bendamustine with mitoxantrone and rituximab. ref name Weide2007 cite journal author Weide R, Hess G, K ppler H, et al. title High anti lymphoma activity of bendamustine mitoxantrone rituximab in rituximab pretreated relapsed ... more details
showed higher response rates in clinical trial s compared to treatment with only rituximab similar ... who no longer respond to rituximab. In patients with relapsed or refractory low grade, follicular ... was 34 20 , comparing ibritumomab to rituximab. ref http www.zevalin.com HealthCarePro efficacy.htm ... that rituximab followed by single agent ibritumomab in a front line setting for patients with MALT ... with rituximab refractory follicular NHL. In December 2007, Cell Therapeutics Inc acquired the U.S. ... more details
cases a bone marrow transplant . The use of rituximab has been established for the treatment of B ... the clinical and economic value of rituximab for the treatment of hematologic malignancies title The Clinical and Economic Value of Rituximab for the Treatment of Hematologic Malignancies publisher ... more details
these therapies, other options include rituximab , ref name pmid12001903 cite journal author Morselli ... after 2 courses of rituximab treatment journal Blood volume 99 issue 9 pages 3478 9 year 2002 ... A, et al. title Efficacy and safety of rituximab in adults warm antibody autoimmune haemolytic ... more details
Oncovin , prednisone Non Hodgkin lymphoma CHOP R or R CHOP CHOP rituximab B cell non Hodgkin ... ICE R ICE chemotherapy regimen ICE rituximab High risk progressive or recurrent lymphomas m BACOD ... Non Hodgkin lymphoma R FCM Rituximab , fludarabine , cyclophosphamide , mitoxantrone B cell ... more details
B cell lymphoma DLBCL &ndash Phase III ref ClinicalTrialsGov NCTNCT01014208 Ofatumumab Versus Rituximab ... lymphoma MCL See also Rituximab , a chimerical anti CD20 antibody Ocrelizumab , a humanized 90 anti ... more details
Unreferenced date December 2009 Infobox disease Name Cytokine release syndrome Image Caption DiseasesDB 34296 ICD10 ICD9 ICDO OMIM MedlinePlus eMedicineSubj eMedicineTopic MeshID Cytokine release syndrome is a common immediate complication occurring with the use of anti T cell antibody infusions such as Anti thymocyte globulin ATG , OKT3 and TGN1412 , but also with the CD 20 antibody rituximab . Severe cases are known as cytokine storm s. The pathogenesis is that the antibody antibodies bind to the T cell receptor, activating the T cells before they are destroyed. The cytokine s released by the activated T cells produce a type of systemic inflammatory response syndrome systemic inflammatory response similar to that found in severe infection characterised by hypotension , pyrexia and rigor medicine rigors . The patient feels very unwell, as if in a high fever &ndash indeed, the cytokine release syndrome is effectively a type of non infective fever. Deaths due to cytokine release syndrome with OKT3 muromonab CD3 have been reported, and it can cause life threatening pulmonary edema if the patient is fluid overloaded. However, if treated appropriately it is usually not dangerous, just extremely unpleasant for the patient. The effect is greatly reduced by using low dose OKT3 e.g. 2 mg instead of 5 mg, slow infusion instead of rapid injection, intravenous administration of an anti histamine such as chlorphenamine and a corticosteroid such as hydrocortisone prior to starting the ATG OKT3 infusion, with further doses of anti histamine and steroid given during the infusion if necessary, Acetaminophine 500 mg by mouth 1 hour before infusion to prevent fever. Moreover, it is recommended that any overhydration to be corrected before the administration the 1st dose either by dialysis or with intravenous furosemide, to prevent the possible development of pulmonary oedema. See also cytokine storm , life threatening massive release of cytokines DEFAULTSORT Cytokine R ... more details
This is a list of specific Wiktionary pharmacological agent pharmacologic agents that are known to be of use in the treatment of cancer , otherwise known as Wiktionary chemotherapeutic agent chemotherapeutic agents . This list is organized by type of agent, though the subsections are not necessarily definitive and are subject to revision. Each drug is listed once at present , though it might fall in more than one subsection. A full alphabetical listing is included after the categorical listing. Expand list date August 2008 Alkylating agents Cyclophosphamide Mechlorethamine Chlorambucil Melphalan Anthracyclines article on anthracycline s Daunorubicin Doxorubicin Epirubicin Idarubicin Mitoxantrone Valrubicin Cytoskeletal disruptors Taxanes Paclitaxel Docetaxel Epothilones article on epothilone s Histone Deacetylase Inhibitors Vorinostat Romidepsin Inhibitors of Topoisomerase II Etoposide Teniposide Tafluposide Kinase Inhibitors Bortezomib Erlotinib Gefitinib Imatinib Vismodegib Monoclonal Antibodies Bevacizumab Cetuximab Ipilimumab Ofatumumab Ocrelizumab Panitumab Rituximab Vemurafenib Nucleotide analogs and precursor analogs Azacitidine Azathioprine Capecitabine Cytarabine Doxifluridine Fluorouracil Gemcitabine Hydroxyurea Mercaptopurine Methotrexate Tioguanine formerly Thioguanine Peptide antibiotics Bleomycin Actinomycin Platinum based agents Carboplatin Cisplatin Oxaliplatin Retinoids Tretinoin Alitretinoin Bexarotene Vinca alkaloids and derivatives Vinblastine Vincristine Vindesine Vinorelbine Full alphabetical listing Actinomycin All trans retinoic acid Azacitidine Azathioprine Bleomycin Bortezomib Carboplatin Capecitabine Cisplatin Chlorambucil Cyclophosphamide Cytarabine Daunorubicin Docetaxel Doxifluridine Doxorubicin Epirubicin Epothilone Etoposide Fluorouracil Gemcitabine Hydroxyurea Idarubicin Imatinib Mechlorethamine Mercaptopurine Methotrexate Mitoxantrone Oxaliplatin Paclitaxel Pemetrexed Teniposide Tioguanine Valrubicin Vinblastine Vincristine Vindesin ... more details
Rituximab has been used in lymphocyte predominant Hodgkin s lymphoma with encouraging results. ref cite ... FA title Rituximab in Hodgkin lymphoma Is the target always a hit? journal Cancer Treat Rev ... more details
is sometimes used at first relapse. For frontline treatment, CHOP with rituximab Rituxan, Mabthera ... side effects mostly hematologic is HyperCVAD , often given as in patient, with rituximab and generally ... results, especially with rituximab. It can be used on some elderly over 65 patients, but seems ... monotherapy, sometimes combined with cyclophosphamide and mitoxantrone, usually with rituximab ... used and effective rituximab monoclonal antibody, sold under the trade name Rituxan or as Mabthera in Europe and Australia . Some say it is a landmark in medicine who? date December 2011 . Rituximab ... response duration. Rituximab essentially tags the cancer cells for destruction by the body. There are newer ... RIT . These include Zevalin and Bexxar . Rituximab has also been used in small numbers of patients ... of rituximab plus thalidomide in patients with relapsed refractory mantle cell lymphoma journal Blood ... cycles of chemotherapy combined with Rituximab. In contrast to these antibody based passive immunotherapies ... more details
and have a poor response to second line rituximab containing treatments even when these regimens involve ... such as rituximab. ref name Davis cite journal last1 Davis first1 TA last2 Czerwinski first2 DK ... lost CD20 expression during treatment with rituximab. Lab tests involving 5 Aza showed that CD20 expression and rituximab sensitivity could be restored in some cases using epigenetic drug treatment ... after treatment with rituximab containing combination chemotherapies its prevalence and clinical ... 2008 08 175208 ref Rituximab Rituxan. The mechanism of action of Rituximab against DLBCL is not fully understood, but studies suggest that rituximab modulates cellular and molecular signal transduction ... polymorphisms alter outcomes of diffuse large B cell lymphoma following rituximab plus CHOP chemotherapy ... more details
MAG neuropathies. Most promising drug RituximabRituximab is considered to be one of the most promising ..., long term studies that have shown that treatment with rituximab can created many immune ..., D., Carpo, M., Padua, L., Zara, G., et al. 2008 . LONG TERM EFFECT OF RITUXIMAB IN ANTI MAG POLYNEUROPATHY ... ref ref name Broglio Broglio, L., & Lauria, G. 2005 . Worsening after rituximab treatment in anti ... more details
rituximab Rituxan , cyclophosphamide Cytoxan doxorubicin Hydroxydaunorubicin , vincristine Oncovin ... title The Clinical and Economic Value of Rituximab for the Treatment of Hematologic Malignancies journal ... oncology 2011 spring 2011 the clinical and economic value of rituximab for the treatment of hematologic ... more details
, often autoimmune. Treatment Avoid cold weather. Treat the underlying lymphoma. Treatment with rituximab ... BT, et al. title Rituximab for primary chronic cold agglutinin disease a prospective study of 37 courses ... more details
in severe disease. Use of rituximab ref name pmid18645332 cite journal author Chandra PA, Margulis Y, Schiff C title Rituximab is useful in the treatment of Felty s syndrome journal Am J Ther volume ... more details
prior to the use of rituximab , which is now included with anthracycline based combination ... . Rituximab has dramatically improved the outcomes of lymphoma patients, and its effect on the prognostic ... more details
dose adjusted EPOCH with Rituxan rituximab . ref name PMID2409217 cite journal author Wyndham ... Phase II Study of Dose Adjusted EPOCH Rituximab in Untreated Diffuse Large B cell Lymphoma with Analysis ... etoposide rituximab ref name pmid17534164 cite journal author Yustein JT, Dang CV title Biology and treatment ... EPOCH with Rituxan rituximab has shown an 8 year survival rate of 91 for low risk, 90 for low intermediate ... more details
Encyclopedia
top
